|Bid||2.7100 x 100|
|Ask||2.7500 x 3100|
|Day's Range||2.6427 - 2.8700|
|52 Week Range||1.1100 - 4.7900|
|PE Ratio (TTM)||-3.82|
|Earnings Date||Jul 27, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
HACKENSACK, N.J., July 17, 2017 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational results for the fourth quarter and fiscal year ended April 30, 2017, on Thursday, July 27, 2017, after market close. The company will host a conference call to discuss the results that day at 4:30 p.m. EST (1:30 p.m. PST). A replay of the call will be available on the Investor tab of the company's website within 72 hours.
Categories: Yahoo Finance Get free summary analysis Champions Oncology, Inc. reports financial results for the quarter ended January 31, 2017. We analyze the earnings along side the following peers of Champions Oncology, Inc. – Aviragen Therapeutics Inc, Charles River Laboratories International, Inc., Exelixis, Inc., Heska Corporation, NanoString Technologies, Inc., Celldex Therapeutics, Inc. and Foundation Medicine, Inc. (AVIR-US, CRL-US, ... Read more (Read more...)
HACKENSACK, N.J., March 16, 2017 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use ...